Table 1.
Correlation between clinical and pathological variables and PDHA1, PDP1 and PDP2 protein expression in prostate cancer.
| Patients – no. | N = 120 | PDHA1 negative | PDHA1 positive | PDP1 negative | PDP1 positive | PDP2 negative | PDP2 positive | |
|---|---|---|---|---|---|---|---|---|
| (N = 91) | (N = 28) | (N = 106) | (N = 13) | (N = 88) | (N = 31) | |||
| Median follow-up time (IQR) – year | 120 | ρ = -0.182 / P = 0.720 | ρ = -0.124 / P = 0.745 | ρ = -0.086 / P = 0.564 | ||||
| 10.5 (9.8-12.4) | 10.9 (1-16) | 9.9 (5.9-15) | 10.6 (1-16) | 9.9 (5.9-15) | 10.7 (1-16) | 10 (5.9-15) | ||
| Median age at surgery (IQR) – year | ρ = 0.057 / P = 0.739 | ρ = 0.041 / P = 0.615 | ρ = 0.011 / P = 0.970 | |||||
| 63 (59-68) | 63 (48-71) | 63.5 (52-73) | 63 (48-73) | 64 (53-69) | 63 (48-73) | 63 (50-70) | ||
| Age at surgery – no. (%) | ρ = 0.015 / P = 0.872 | ρ = -0.027 / P = 0.767 | ρ = 0.013 / P = 0.888 | |||||
| < 65 year | 78 (65) | 60 (66) | 18 (64) | 69 (65) | 9 (69) | 58 (66) | 20 (64.5) | |
| > 65 year | 42 (35) | 31 (34) | 10 (36) | 37 (35) | 4 (31) | 30 (34) | 11 (35.5) | |
| Preoperative PSA – no. (%) | ρ = -0.100 / P = 0.440 | ρ = -0.082 / P = 0.819 | ρ = -0.168 / P = 0.311 | |||||
| ≤ 6 ng/ml | 36 (30) | 25 (27.5) | 11 (39.5) | 31 (29) | 5 (38.5) | 23 (26) | 13 (42) | |
| > 6 ng/ml and ≤ 10 ng/ml | 43 (35) | 34 (37.5) | 8 (28.5) | 37 (35) | 5 (38.5) | 32 (36.5) | 11 (35.5) | |
| > 10 ng/ml and ≤ 20 ng/ml | 33 (27.5) | 25 (27.5) | 8 (28.5) | 30 (28) | 3 (23) | 26 (29.5) | 7 (22.5) | |
| > 20 ng/ml | 4 (3.3) | 4 (4.5) | 0 (0) | 4 (4) | 0 (0) | 4 (4.5) | 0 (0) | |
| Missing | 4 (3.3) | 3 (3) | 1 (3.5) | 4 (4) | 0 (0) | 3 (3.5) | 0 (0) | |
| Gleason grade – no. (%) | ρ = -0.051 / P = 0.389 | ρ = -0.004 / P = 0.545 | ρ = 0.065 / P = 0.480 | |||||
| ≤ 6 | 72 (60) | 55 (60.5) | 16 (57) | 64 (60) | 7 (54) | 55 (62.5) | 16 (52) | |
| 3+4 | 22 (18) | 14 (15.5) | 8 (28.5) | 18 (17) | 4 (31) | 14 (16) | 8 (26) | |
| 4+3 | 7 (6) | 6 (6.5) | 1 (3.5) | 7 (7) | 0 (0) | 6 (7) | 1 (3) | |
| ≥ 8 | 19 (16) | 16 (17.5) | 3 (11) | 17 (16) | 2 (15) | 13 (14.5) | 6 (19) | |
| Stage - no. (%) | ρ = 0.107 / P = 0.243 | ρ = 0.191 / P = 0.037 | ρ = - 0.024 / P = 0.797 | |||||
| T2 | 99 (82.5) | 77 (84.5) | 21 (75) | 90 (85) | 8 (61.5) | 72 (82) | 26 (84) | |
| T3 | 21 (17.5) | 14 (15.5) | 7 (25) | 16 (15) | 5 (38.5) | 16 (18) | 5 (16) | |
| Surgical margins – no. (%) | ρ = -0.069 / P = 0.454 | ρ = -0.084 / P = 0.360 | ρ = -0.1 08 / P = 0.239 | |||||
| Negative | 78 (65) | 58 (64) | 20 (71.5) | 68 (64) | 10 (77) | 55 (62.5) | 23 (74) | |
| Positive | 42 (35) | 33 (36) | 8 (28.5) | 38 (36) | 3 (23) | 33 (37.5) | 8 (26) | |
| Extracapsular extension– no. (%) | ρ = 0.122 / P = 0.185 | ρ = 0.203 / P = 0.027 | ρ = -0.011 / P = 0.907 | |||||
| No | 100 (83) | 78 (86) | 21 (75) | 91 (86) | 8 (61.5) | 73 (83) | 26 (84) | |
| Yes | 20 (17) | 13 (14) | 7 (25) | 15 (14) | 5 (38.5) | 15 (17) | 5 (16) | |
| Seminal vesicle invasion – no. (%) | ρ = -0.017 / P = 0.849 | ρ = 0.061 / P = 0.506 | ρ = -0.124 / P = 0.175 | |||||
| No | 20 (17) | 87 (96) | 27 (96.5) | 102 (96) | 12 (92) | 83 (94.5) | 31 (100) | |
| Yes | 100 (83) | 4 (4) | 1 (3.5) | 4 (4) | 1 (8) | 5 (5.5) | 0 (0) | |
| CAPRA-S risk group – no. (%)* | ρ = -0.111 / P = 0.529 | ρ = -0.005 / P = 0.388 | ρ = -0.1 45 / P = 0.240 | |||||
| Low | 48 (40) | 35 (38.5) | 13 (46.5) | 44 (41.5) | 4 (31) | 36 (41) | 12 (39) | |
| Intermediate | 44 (37) | 34 (37) | 9 (32) | 37 (35) | 6 (46) | 34 (39) | 9 (29) | |
| High | 9 (8) | 8 (9) | 1 (3.5) | 9 (8.5) | 0 (0) | 9 (10) | 0 (0) | |
| Missing | 19 (15) | 14 (25.5) | 5 (18) | 16 (15) | 3 (23) | 9 (10) | 10 (32) | |
| Biochemical recurrence – no. (%) | ρ = -0.027 / P = 0.769 | ρ = -0.084 / P = 0.360 | ρ = 0.013 / P = 0.888 | |||||
| Negative | 78 (65) | 59 (65) | 19 (68) | 68 (64) | 10 (77) | 58 (66) | 20 (64.5) | |
| Positve | 42 (35) | 32 (35) | 9 (32) | 38 (36) | 3 (23) | 30 (34) | 11 (35.5) | |
| Disease-free survival – no. (%) | ρ = 0.105 / P = 0.299 | ρ = 0.074 / P = 0.463 | ρ = -0.046 / P = 0.652 | |||||
| Yes | 41 (34) | 32 (35) | 8 (28) | 37 (35) | 3 (23) | 28 (32) | 12 (39) | |
| No | 58 (48) | 41 (45) | 17 (61) | 51 (48) | 7 (54) | 43 (49) | 15 (48) | |
| Missing | 21 (18) | 18 (20) | 5 (11) | 18 (17) | 3 (23) | 17 (19) | 4 (13) | |
*The CAPRA-S scores were categorized to give the three risk groups: Low risk if sscore 0-2; Intermediate risk if score 3 to 5; High risk if score 6 to 12.
Spearsman´s correlation ρ (95% CI) / P value.
IQR, interquartile range; PSA, prostate-specific antigen; AR, androgen receptor.